Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus.

Front Endocrinol (Lausanne) · 2024 · PMC10961402 · PMID 38529396

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

These results indicated that cetagliptin showed a trend of decline in plasma glucose and a trend of improvement of pancreatic β-cell function.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.